CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.1.1. DISORDER TYPE
1.1.2. DRUG CLASS
1.1.3. DISTRIBUTION CHANNEL
1.2. RESEARCH METHODOLOGY
1.3. INFORMATION PROCUREMENT
1.3.1. PURCHASED DATABASE
1.3.2. GVR’S INTERNAL DATABASE
1.3.3. SECONDARY SOURCES
1.3.4. PRIMARY RESEARCH
1.3.5. DETAILS OF PRIMARY RESEARCH
1.4. INFORMATION OR DATA ANALYSIS
1.4.1. DATA ANALYSIS MODELS
1.5. MARKET FORMULATION & VALIDATION
1.6. MODEL DETAILS
1.6.1. COMMODITY FLOW ANALYSIS (MODEL 1)
1.6.2. APPROACH 1: COMMODITY FLOW APPROACH
1.6.3. VOLUME PRICE ANALYSIS (MODEL 2)
1.6.4. APPROACH 2: VOLUME PRICE ANALYSIS
1.7. LIST OF SECONDARY SOURCES
1.8. LIST OF PRIMARY SOURCES
1.9. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET OUTLOOK
2.2. DISORDER TYPE AND DRUG CLASS OUTLOOK
2.3. DISTRIBUTION CHANNEL OUTLOOK
2.4. COMPETITIVE INSIGHTS
CHAPTER 3. DIABETIC NEUROPATHY TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT MARKET OUTLOOK
3.1.2. RELATED/ANCILLARY MARKET OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. MARKET DRIVER ANALYSIS
3.2.1.1. INCREASING PREVALENCE OF DIABETES
3.2.1.2. ROBUST PRODUCT PIPELINE
3.2.1.3. INCREASING INVESTMENTS IN R&D
3.2.2. MARKET RESTRAINT ANALYSIS
3.2.2.1. STRINGENT REGULATORY SCENARIO
3.2.2.2. SAFETY CONCERNS WITH CURRENT THERAPIES
3.3. DIABETIC NEUROPATHY TREATMENT MARKET ANALYSIS TOOLS
3.3.1. PORTER’S FIVE FORCES ANALYSIS
3.3.2. PESTEL ANALYSIS
CHAPTER 4. DIABETIC NEUROPATHY TREATMENT: DISORDER TYPE ESTIMATES & TREND ANALYSIS
4.1. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: DISORDER TYPE SEGMENT DASHBOARD
4.2. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET BY DISORDER TYPE MOVEMENT OUTLOOK
4.3. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SIZE & TREND ANALYSIS, BY DISORDER TYPE, 2024 - 2033
4.4. PERIPHERAL NEUROPATHY
4.4.1. PERIPHERAL NEUROPATHY MARKET ESTIMATES AND FORECAST, 2024 - 2033
4.5. AUTONOMIC NEUROPATHY
4.5.1. AUTONOMIC NEUROPATHY MARKET ESTIMATES AND FORECAST, 2024 - 2033
4.6. PROXIMAL NEUROPATHY
4.6.1. PROXIMAL NEUROPATHY MARKET ESTIMATES AND FORECAST, 2025 - 2033
4.7. FOCAL NEUROPATHY
4.7.1. FOCAL NEUROPATHY MARKET ESTIMATES AND FORECAST, 2025 - 2033
CHAPTER 5. DIABETIC NEUROPATHY TREATMENT: DRUG CLASS ESTIMATES & TREND ANALYSIS
5.1. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: DRUG CLASS SEGMENT DASHBOARD
5.2. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET BY DRUG CLASS MOVEMENT OUTLOOK
5.3. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SIZE & TREND ANALYSIS, BY DRUG CLASS, 2024 - 2033
5.4. CAPSAICIN
5.4.1. CAPSAICIN MARKET ESTIMATES AND FORECAST 2024 - 2033
5.5. OPIOID
5.5.1. OPIOID MARKET ESTIMATES AND FORECAST 2024 - 2033
5.5.2. MORPHINE
5.5.2.1. MORPHINE MARKET ESTIMATES AND FORECAST 2024 - 2033
5.5.2.2. OTHERS
5.5.2.3. OTHERS MARKET ESTIMATES AND FORECAST 2024 - 2033
5.6. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6.1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MARKET ESTIMATES AND FORECAST 2024 - 2033
5.6.2. IBUPROFEN
5.6.2.1. IBUPROFEN MARKET ESTIMATES AND FORECAST 2024 - 2033
5.6.3. NAPROXEN
5.6.3.1. NAPROXEN MARKET ESTIMATES AND FORECAST 2024 - 2033
5.6.4. OTHERS
5.6.4.1. OTHERS MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7. ANTIDEPRESSANTS
5.7.1. ANTIDEPRESSANTS MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.2. TRICYCLIC ANTIDEPRESSANTS (TCAS)
5.7.2.1. TRICYCLIC ANTIDEPRESSANTS (TCAS) MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.2.1.1. AMITRIPTYLINE
5.7.2.2. AMITRIPTYLINE MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.2.2.1. IMIPRAMINE
5.7.2.3. IMIPRAMINE MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.2.3.1. OTHERS
5.7.2.4. OTHERS MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.3. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
5.7.3.1. SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.3.1.1. DULOXETINE
5.7.3.2. DULOXETINE MARKET ESTIMATES AND FORECAST 2024 - 2033
5.7.3.2.1. OTHERS
5.7.3.3. OTHERS ESTIMATES AND FORECAST 2024 - 2033
5.7.4. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
5.7.4.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) ESTIMATES AND FORECAST 2024 - 2033
5.7.4.1.1. CITALOPRAM
5.7.4.2. CITALOPRAM ESTIMATES AND FORECAST 2024 - 2033
5.7.4.2.1. PAROXETINE
5.7.4.3. PAROXETINE ESTIMATES AND FORECAST 2024 - 2033
5.7.4.3.1. OTHERS
5.7.4.4. OTHERS ESTIMATES AND FORECAST 2024 - 2033
5.7.5. ANTICONVULSANT DRUGS
5.7.5.1. ANTICONVULSANT DRUGS ESTIMATES AND FORECAST 2024 - 2033
5.7.5.1.1. GABAPENTIN
5.7.5.1.2. GABAPENTIN ESTIMATES AND FORECAST 2024 - 2033
5.7.5.1.3. PREGABALIN
5.7.5.1.4. PREGABALIN ESTIMATES AND FORECAST 2024 - 2033
5.7.5.1.5. TOPIRAMATE
5.7.5.1.6. TOPIRAMATE ESTIMATES AND FORECAST 2024 - 2033
5.7.5.1.7. OTHERS
5.7.5.1.8. OTHERS ESTIMATES AND FORECAST 2024 - 2033
5.8. OTHER
5.8.1. OTHER ESTIMATES AND FORECAST 2024 - 2033
CHAPTER 6. DIABETIC NEUROPATHY TREATMENT: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET: DISTRIBUTION CHANNEL SEGMENT DASHBOARD
6.2. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET BY DISTRIBUTION CHANNEL MOVEMENT OUTLOOK
6.3. GLOBAL DIABETIC NEUROPATHY TREATMENT MARKET SIZE & TREND ANALYSIS, BY DISTRIBUTION CHANNEL, 2024 - 2033
6.4. HOSPITALS PHARMACIES
6.4.1. HOSPITAL PHARMACIES ESTIMATES AND FORECAST 2024 - 2033
6.5. RETAIL PHARMACIES
6.5.1. RETAIL PHARMACIES ESTIMATES AND FORECAST 2024 - 2033
6.6. OTHER
6.6.1. OTHER ESTIMATES AND FORECAST 2024 - 2033
CHAPTER 7. DIABETIC NEUROPATHY TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. REGIONAL MARKET DASHBOARD
7.2. MARKET SIZE, & FORECASTS TREND ANALYSIS, 2025 - 2033:
7.3. NORTH AMERICA
7.3.1. U.S.
7.3.1.1. KEY COUNTRY DYNAMICS
7.3.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.3.1.3. COMPETITIVE SCENARIO
7.3.1.4. U.S. MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.3.2. CANADA
7.3.2.1. KEY COUNTRY DYNAMICS
7.3.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.3.2.3. COMPETITIVE SCENARIO
7.3.2.4. CANADA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4. EUROPE
7.4.1. UK
7.4.1.1. KEY COUNTRY DYNAMICS
7.4.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.1.3. COMPETITIVE SCENARIO
7.4.1.4. UK MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.2. GERMANY
7.4.2.1. KEY COUNTRY DYNAMICS
7.4.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.2.3. COMPETITIVE SCENARIO
7.4.2.4. GERMANY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.3. FRANCE
7.4.3.1. KEY COUNTRY DYNAMICS
7.4.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.3.3. COMPETITIVE SCENARIO
7.4.3.4. FRANCE MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.4. ITALY
7.4.4.1. KEY COUNTRY DYNAMICS
7.4.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.4.3. COMPETITIVE SCENARIO
7.4.4.4. ITALY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.5. SPAIN
7.4.5.1. KEY COUNTRY DYNAMICS
7.4.5.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.5.3. COMPETITIVE SCENARIO
7.4.5.4. SPAIN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.6. NORWAY
7.4.6.1. KEY COUNTRY DYNAMICS
7.4.6.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.6.3. COMPETITIVE SCENARIO
7.4.6.4. NORWAY MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.7. SWEDEN
7.4.7.1. KEY COUNTRY DYNAMICS
7.4.7.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.7.3. COMPETITIVE SCENARIO
7.4.7.4. SWEDEN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.4.8. DENMARK
7.4.8.1. KEY COUNTRY DYNAMICS
7.4.8.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.4.8.3. COMPETITIVE SCENARIO
7.4.8.4. DENMARK MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5. ASIA PACIFIC
7.5.1. JAPAN
7.5.1.1. KEY COUNTRY DYNAMICS
7.5.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.1.3. COMPETITIVE SCENARIO
7.5.1.4. JAPAN MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.2. CHINA
7.5.2.1. KEY COUNTRY DYNAMICS
7.5.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.2.3. COMPETITIVE SCENARIO
7.5.2.4. CHINA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.3. INDIA
7.5.3.1. KEY COUNTRY DYNAMICS
7.5.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.3.3. COMPETITIVE SCENARIO
7.5.3.4. INDIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.4. AUSTRALIA
7.5.4.1. KEY COUNTRY DYNAMICS
7.5.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.4.3. COMPETITIVE SCENARIO
7.5.4.4. AUSTRALIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.5. SOUTH KOREA
7.5.5.1. KEY COUNTRY DYNAMICS
7.5.5.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.5.3. COMPETITIVE SCENARIO
7.5.5.4. SOUTH KOREA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.5.6. THAILAND
7.5.6.1. KEY COUNTRY DYNAMICS
7.5.6.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.5.6.3. COMPETITIVE SCENARIO
7.5.6.4. THAILAND MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6. LATIN AMERICA
7.6.1. BRAZIL
7.6.1.1. KEY COUNTRY DYNAMICS
7.6.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.6.1.3. COMPETITIVE SCENARIO
7.6.1.4. BRAZIL MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.2. MEXICO
7.6.2.1. KEY COUNTRY DYNAMICS
7.6.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.6.2.3. COMPETITIVE SCENARIO
7.6.2.4. MEXICO MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.6.3. ARGENTINA
7.6.3.1. KEY COUNTRY DYNAMICS
7.6.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.6.3.3. COMPETITIVE SCENARIO
7.6.3.4. ARGENTINA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7. MEA
7.7.1. SOUTH AFRICA
7.7.1.1. KEY COUNTRY DYNAMICS
7.7.1.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.7.1.3. COMPETITIVE SCENARIO
7.7.1.4. SOUTH AFRICA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7.2. SAUDI ARABIA
7.7.2.1. KEY COUNTRY DYNAMICS
7.7.2.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.7.2.3. COMPETITIVE SCENARIO
7.7.2.4. SAUDI ARABIA MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7.3. UAE
7.7.3.1. KEY COUNTRY DYNAMICS
7.7.3.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.7.3.3. COMPETITIVE SCENARIO
7.7.3.4. UAE MARKET ESTIMATES AND FORECASTS 2024 - 2033
7.7.4. KUWAIT
7.7.4.1. KEY COUNTRY DYNAMICS
7.7.4.2. REGULATORY FRAMEWORK/ REIMBURSEMENT STRUCTURE
7.7.4.3. COMPETITIVE SCENARIO
7.7.4.4. KUWAIT MARKET ESTIMATES AND FORECASTS 2024 - 2033
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. RECENT DEVELOPMENTS & IMPACT ANALYSIS, BY KEY MARKET PARTICIPANTS
8.2. COMPANY/COMPETITION CATEGORIZATION
8.2.1. INNOVATORS
8.3. PFIZER. INC
8.3.1. LIST OF KEY DISTRIBUTORS AND CHANNEL PARTNERS
8.3.2. KEY CUSTOMERS
8.3.3. KEY COMPANY MARKET SHARE ANALYSIS, 2023
8.3.4. ABBOTT
8.3.4.1. COMPANY OVERVIEW
8.3.4.2. FINANCIAL PERFORMANCE
8.3.4.3. PRODUCT BENCHMARKING
8.3.4.4. STRATEGIC INITIATIVES
8.3.5. JANSSEN PHARMACEUTICALS, INC
8.3.5.1. COMPANY OVERVIEW
8.3.5.2. FINANCIAL PERFORMANCE
8.3.5.3. PRODUCT BENCHMARKING
8.3.5.4. STRATEGIC INITIATIVES
8.3.6. ELI LILLY AND COMPANY
8.3.6.1. COMPANY OVERVIEW
8.3.6.2. FINANCIAL PERFORMANCE
8.3.6.3. PRODUCT BENCHMARKING
8.3.6.4. STRATEGIC INITIATIVES
8.3.7. GLENMARK PHARMACEUTICALS LTD
8.3.7.1. COMPANY OVERVIEW
8.3.7.2. FINANCIAL PERFORMANCE
8.3.7.3. PRODUCT BENCHMARKING
8.3.7.4. STRATEGIC INITIATIVES
8.3.8. LUPIN PHARMACEUTICALS
8.3.8.1. COMPANY OVERVIEW
8.3.8.2. FINANCIAL PERFORMANCE
8.3.8.3. PRODUCT BENCHMARKING
8.3.8.4. STRATEGIC INITIATIVES
8.3.9. NOVARTIS
8.3.9.1. COMPANY OVERVIEW
8.3.9.2. FINANCIAL PERFORMANCE
8.3.9.3. PRODUCT BENCHMARKING
8.3.9.4. STRATEGIC INITIATIVES
8.3.10. ASTELLAS PHARMA INC
8.3.10.1. COMPANY OVERVIEW
8.3.10.2. FINANCIAL PERFORMANCE
8.3.10.3. PRODUCT BENCHMARKING
8.3.10.4. STRATEGIC INITIATIVES
8.3.11. BOEHRINGER INGELHEIM GMBH
8.3.11.1. COMPANY OVERVIEW
8.3.11.2. FINANCIAL PERFORMANCE
8.3.11.3. PRODUCT BENCHMARKING
8.3.11.4. STRATEGIC INITIATIVES
8.3.12. OTHERS
8.3.12.1. COMPANY OVERVIEW
8.3.12.2. FINANCIAL PERFORMANCE
8.3.12.3. PRODUCT BENCHMARKING
8.3.12.4. STRATEGIC INITIATIVES
CHAPTER 9. ANALYST PERSPECTIVE/ CONCLUSION
著作権 ©2022 無断複写・転載を禁じます
